Nordic announces expanded use of Imunavune authorized

Bavarian Nordic recently announced that the U.S. government has expanded the population eligible to receive Imvamune, its attenuated smallpox vaccine, in case of an emergency.

Despite limited available clinical data, the U.S. government will authorize the use of Imvamune to protect individuals of all ages with HIV or atopic dermatitis from smallpox infection. Children, pregnant women and nursing mothers with HIV or atopic dermatitis are also eligible to receive the vaccine.

Imvamune is marketed as a smallpox vaccine alternative for individuals with compromised immune systems.

"Bavarian Nordic is pleased that our continuing development of Imvamune supports the United States' goal of developing medical countermeasures for at-risk populations like children with atopic dermatitis," Bavarian Nordic President and CEO Anders Hedegaard said. "We are committed to ensuring the most vulnerable populations have access to medical countermeasures suited for their age and condition."

In the 2010 Broad Agency Announcement for Medical Countermeasure Development, the U.S. Biomedical Advanced Research and Development Authority stressed a need to find a sufficient quantity of a smallpox vaccine suitable to administer to 28 million people with atopic dermatitis and 10 million people with compromised immune systems.

The U.S. government recently ordered 20 million Imvamune doses and Nordic expects delivery to be complete by 2013. Nordic and BARDA are also collaborating on a freeze-dried version of the vaccine that potentially has a longer shelf-life.